Summanr Flunarizine. a diphenylpiperazine calcium channel blocker. is known to increase tumour blood flow. It also interferes with calmodulin function. repair of DNA damage and drug resistance associated with P-glvcoprotein. Flunarizine was tested for its ability to modulate either cyclophosphamide-or melphalaninduced growth delay for a drug-resistant rhabdomyosarcoma xenograft (TE-671 MR) and the drug-sensitive parent line (TE-671). in which P-glycoprotein is not involved in the mechanism of drug resistance. Tumour blood flow was increased by 30% after a flunarizine dose of 4 mg kg-'. but no modification in growth delay was induced by melphalan (12 mg kg-'). In contrast. a 60 mg kg-' dose of flunarizine had no effect on tumour blood flow. but the same dose created significant enhancement in melphalan-induced tumour regrowth delay in both tumour lines. The dose-modifying factor for flunarizine as an adjuvant to melphalan was approximately 2 for both tumour lines. Although blood flow measurements were not performed with the combination of flunarizine and melphalan, the results from flunarizine alone suggested that augmentation of melphalan cytotoxicity is not mediated by changes in blood flow. In contrast. flunarizine did not affect drug sensitivity to cyclophosphamide in groups of animals bearing the drug-sensitive parent tumour line. These results suggest that the mechanism of drug sensitivity modification by flunarizine is not related to modification of tumour blood flow, but may be mediated by modification of transport mechanisms that are differentially responsible for cellular uptake and retention of melphalan as compared With cyclophosphamide.
Melphalan is a nitrogen mustard-based alkylating agent active against a broad spectrum of malignancies. including medulloblastoma and rhabdomyosarcoma (Horowitz et al., 1988; Friedman et al.. 1989) . Unfortunately, development of melphalan resistance mediated by altered drug transport. increased drug detoxification or increased repair of DNA interstrand cross-links (Redwood and Colvin, 1980; Parsons et al., 1981; Somfai-Relle et al., 1984; Gupta et al., 1989) frequently prevents successful therapy of human neoplasia with this agent, thus supporting development of therapeutic approaches that are effective in bypassing or overcoming drug resistance.
We have previously shown that melphalan resistance in a human rhabdomyosarcoma line (TE-671 MR) is associated with decreased drug accumulation relative to the drugsensitive parent line (Lilley et al.. 1991) . Thus, methods that increase drug uptake within tumour might increase the therapeutic efficacy of melphalan in the resistant line. It has been suggested that reversal of alkylator drug resistance by calcium channel blockers may be due to an increase in drug delivery as a consequence of improved blood flow (Stewart and Evans, 1989) .
Flunarizine. a diphenylpiperazine calcium channel blocker, was selected as an agent to test whether increased tumour blood flow would lead to increased drug efficacy in this model system. There were several reasons for this choice. First, studies show that flunarizine increased blood flow to tumours (Kaelin et al.. 1984: Hill and Stirling, 1987; Vaupel and Menke, 1989; Dewhirst et al.. 1992a) . The effects are more prominent in tumours that are hypoxic (Fenton and Sutherland, 1992) , and blood flow modification can be achieved at dosages that do not alter cardiovascular function (Kaelin et al.. 1984; Dewhirst et al., 1992a) . Both the parent and resistant sublines of TE-671 contain hypoxic regions in vivo (Lilley et al., 1991) . Thus. the agent would be expected to be effective by increasing blood flow in both lines. A second reason for choosing this agent is its reported activity as an inhibitor of calmodulin. Calmodulin inhibitors have been shown to restore drug sensitivity to tumour cells with multiple drug resistance (MDR) mediated by increased Pglycoprotein (Stewart and Evans. 1989 ). However. a few reports have suggested that calmodulin inhibitors also reverse resistance to drugs not characteristically associated with MDR. such as cyclophosphamide (Hait et al.. 1989) , cisplatin (Kikuchi et al., 1986) . nitrosoureas (Rose et al., 1978) and bleomycin (Lazo et al., 1986) .
Calmodulin inhibitors have also been reported to reduce intracellular glutathione concentrations (Shenoy et al.. 1983) . and elevated glutathione content has proven responsible in part for TE-671 MR resistance to melphalan (Rosenberg et al., 1989) . thus, flunarizine could alter drug resistance in this model by reducing glutathione content.
We now report that flunarizine. administered at 4 mg kg-' (i.p.). increases blood flow to TE-671 by 30%. but has no effect on either TE-671 or TE-671 MR with regard to melphalan-induced tumour regrowth delay. In contrast, a flunarizine dosage of 60mgkg-' (i.p.) to both the resistant and parent tumour lines significantly prolongs growth delay, although it has no effect on tumour blood flow. This enhancement of growth delay is accompanied by an increase in tumour-plasma melphalan concentration ratios relative to control tumours receiving melphalan alone.
Materials and methods

Animals and tumour models
All studies used male or female athymic BALB/c mice (nu nu genotype, 6 weeks or older) maintained as previously described (Redwood and Colvin, 1980; Bullard et al., 1981 (McAllister et al.. 1977 : Stratton et al.. 1989 ) and the melphalan-resistant subline TE-671 MR (Rosenberg et al.. 1989) were used for all studies. Subcutaneous transplantation of tumour homogenates (50pl) into the right flank of mice were conducted as previously described (Friedman et al.. 1986a Response of xenografts was assessed by growth delay. the difference in days between the median time for the tumours of treated (T) and control (C) animals to reach a volume of five times greater than the volume at the time of original treatment (T -C). Tumour regressions were defined as tumours that decreased in size over two successive measurements. relative to the volume at the day of treatment. We report data in terms of tumour volumes because we have previously shown in this laboratorx that strong correlations exist between tumour volume measurements done with this method and direct measures of tumour weight (Bullard et al., 1981) .
.4nalisis of melphalan uptak-e Animals bearing TE-671 MR (six animals per group) were treated with melphalan (24 mg kg-') via i.p. injection with or without a prior dose of flunanrzine (60 mg kg-i.p.). Animals were killed by cervical dislocation at 30. 60 and 120 min after the melphalan injection. Blood was obtained immediately by cardiac puncture. and the serum was separated by centrifugation and placed on dry ice. Subcutaneous xenografts were simultaneously resected. weighed and frozen in liquid nitrogen. After thawing. they were homogenised with 10% perchloric acid (5:1, w v). Melphalan concentrations in plasma and tumour samples were measured by high-pressure liquid chromatography as previously described (Friedman et al. 1986b) . Results were reported as mean tumour-plasma ratios.
Statistical methods
The Wilcoxon rank order test was used to evaluate growth delays and melphalan tumour-plasma ratios. The Fisher exact test was used for tumour regression (Friedman et al.. 1986a) . Repeated measures analysis of variance was used to test for relative changes between baseline (pretreatment) perfusion rate and time-monitored perfusion rates after flunarizine administration (Snedecor and Cochran, 1967) . The null hypothesis was that drug administration caused no relative change in perfusion. A two-tailed paired t-test was used to compare MAPs before and after flunarizine administration.
Results
Ph-isiological studies MAP was measured in four anaesthetised animals (ketamine/ xylazine) and two conscious animals (as described in Materials and methods) before and up to 60 min after administration of flunarizine (4 mg kg-'). In the anaesthetised animals. MAP averaged 75.4 ± 6.6 mmHg (mean ± s.d.) before drug administration and 75.4 ± 6.6 mmHg after. In the conscious animals. mean baseline MAP was 102.5 mmHg and averaged 102.8 mmHg after drug administration. Thus. a dose of 4 mg kg-' flunarizine created no detectable change in MAP in either anaesthetised or conscious mice. MAP was also measured in six conscious mice that received 60 mg kg-' flunarizine. In this group, MAP averaged 91.5 ± 8.8 mmHg and 75.1 ± 9.1 mmHg before and after flunarizine administration respectively. The observed change in MAP was significant (P = 0.0337 two-tailed, paired t-test) and represented an 18% drop relative to average predrug MAP.
Relative changes in muscle and tumour blood flow were measured in six and nine mice bearing TE-671 xenografts receiving 4 and 60 mg kg-' flunarizine respectively (Figure 1) . A dose of 4 mg kg-increased tumour blood flow by 30% on average, which was statistically significant (P<0.05). In con- (Table II) . Flunarizine alone produced no significant growth delay at 4 mg kg-' or 60 mg kg-'. Combination therapy with melphalan plus flunarizine created growth delays of 2.5 and 2.2 days with 4 mg kg-' flunarizine and 2.2 and 2.8 days with 8 mg kg-' flunarizine with differences that were not statistically significant (P> 0.10) as compared with melphalan alone. Combination therapy with melphalan plus flunarinzine at 60 mg kg-' induced an increase in growth delay (10.3 days) that was statistically significant (P<0.01) when compared with melphalan alone (4.1 days). Tumour regressions with the same treatment were not statistically (P>0.10) significant when compared with melphalan alone.
Comparisons of growth delays at 2.4 and 12mgkg-' revealed enhancement of growth delay without an increase in mortality; no animals died in any of these treatment groups, with observation times of over 30 days post treatment. The dose-modifying factor was 2.3 over this melphalan dose range (Figure 2b ). Cyclophosphamide at 115, 230 and 345 mg kg-' yielded growth delays of 9, 13.4 and 17.7 days respectively. When flunarizine was added at a dose of 60 mg kg-', growth delays were 11.7, 14.6 and 18.1 days respectively. All of these delays were significant when compared with control animals (P <0.001 in all cases), but there were no significant differences between the groups with respect to presence or absence of flunarizine.
No regressions were observed in any controls or flunarizine-treated animals.
Effect offlunarizine on plasma and tumour melphalan levels In mice bearing TE-671 MR, plasma levels of melphalan appeared higher for the flunarizine group, but the differences were not significant (P>0.25 for all time points) (Figure 3a) . In contrast, the mean tumour-plasma ratio of melphalan was significantly higher in the flunarizine treatment group at 120 mi after treatment (P = 0.04) (Figure 3b ). Verapamil, diltiazem and nitrendipine stimulated melphalan uptake in this cell line, albeit to varying levels of efficacy. These same drugs also have some levels of calmodulin inhibition, but treatment with the calmodulin inhibitor trifluoperazine actually reduced uptake. Therefore, the ability of these drugs to affect cellular uptake is probably related to their calcium channel blocking capability and not their activity as calmodulin inhibitors. We have previously published the plasma pharmacokinetics of melphalan in TE-671-bearing mice and showed a half-life of 29.9 min (Friedman et al., 1986b) . These results are consistent with the published results of Lee and Workman (1986) , who found a half-life of 26.1 min. The results of the present study are not inconsistent with these prior reports, except that peak plasma levels were less than those we previously observed.
It is generally believed that calcium channel blockers exert their chemosensitising effect on multidrug resistance (MDR) by reducing drug egress from cells. The mechanism by which this ogcurs is not known but is thought to be related to P-glycoprotein antagonism (Stewart and Evans, 1989) . It has been suggested previously that calcium channel blockers may reverse non-MDR-associated resistance via their effects on tumour blood flow (Stewart and Evans, 1989) . Our results clearly demonstrate, however, that modification of drug toxicity in this model system by flunarizine is not related to an increase in blood flow, since the increase in blood flow observed at the 4 mg kg1' flunarizin dose was not associated with any change in tumour growth delay as compared with melphalan alone. In contrast, the increased tumour concentrations of melphalan associated with the higher lunarzine dose (60mgkg-') were not associated with blood flow changes. It is possible that the combination of high-dose flunarizine and melphalan might have caused changes in blood flow that were not seen with flunarizine alone; but given the effects of flunarizine on blood viscosity (see below), this is an unlikely outcome. These results suggest that the mechanism of chemosensitisation in this non-MDR-resistant xenograft model relates to increased retention of melphalan in tissue that is not regulated by modification of tumour blood flow. Adams et al. (1989) reported similar results for the calcium channel blocker nifedipine, although the investigators did not measure tumour blood flow directly. Instead, they measured radiobiological hypoxic fraction, which was not altered at a dose of 10mg kg-' (i.p.), and inferred from those results that no change in tumour blood flow occurred.
The dose-modifying factor for 60 mg kg-' flunarizine added to melphalan was approximately 2 for both cell lines. These results, in combination with the increased tumourplasma ratios for melphalan concentration, suggest that drug egress mechanisms are operational in both lines and that flunarizne affects these mechanisms to the same extent in both cell lines.
Flunarizie may also increase the activity of melphalan via its activity as a calmodulin inhibitor (Lugnier et al., 1984) . Flunarizine is known to be a potent calmodulin inhibitor, exhibiting activity in the 3-4pM range in vitro. In smooth muscle preparations, calmodulin-induced contractions were inhibited at concentrations greater than 10 1M. Thus, it is likely that concentrations greater than 1O JM would be needed to affect calmodulin in vivo. The threshold for calmodulin inhibition may explain why the lower concentration of flunariine was ineffective in modulating melphalan toxicity in the TE-671 lines. The 4mgkg-' dose would yield tissue concentrations in the 5-8 pM range, whereas the 60mgkg-' dose would yield concentrations in the 1OiM range. There is evidence that calmodulin inhibitors interfere with DNA repair. For example, decreased repair of bleomycin-induced DNA damage has been observed in the presence of the calmodulin inhibitor trifluoperazine (Chafouleas et al., 1984) . Thus, it is possible that flunarizine was acting to reduce repair of DNA-protein cross-links induced by melphalan. However, no enhancement of cyclophosphamide toxicity was observed, so the likelihood that this mechanism was operational is diminished. In addition, the aforementioned study in L5178Y lymphoblasts showed decreased drug uptake with calmodulin inhibitors rather than increased uptake (Miller et al., 1992) .
It has been reported that calmodulin inhibitors can also reduce cellular non-protein thiol content (Shenoy et al., 1983) . In prior work, glutathione depletion by L-buthioninesulphoximine created relative increases in growth delay of 37% in TE-671 and 95-113% in TE-671 MR (Rosenberg et al., 1989) . It is believed that part of the mechanism of resistance in TE-671 MR is due to elevation of glutathione. The effect of calmodulin inhibitors on thiols, however, occurs at much higher drug concentrations than those achievable in vivo. It is not clear, then, whether glutathione depletion is playing a role in the modification of drug resistance in this series of experiments. Additional work would be needed to investigate this further.
The mechanism by which flunarizine modifies tumour blood flow is speculated to be either vasodilation or a change in blood viscosity. We recently demonstrated in a rat tumour model that the increase in tumour blood flow observed with flunarizine, given at 1 mg kg-' i.v., is accompanied by a significant increase in perivascular oxygenation within the tumour (Dewhirst et al., 1992b) . Furthermore, the increase in blood flow and oxygenation is not attributable to changes in cardiovascular function, tumour feeding vessel diameter, haemoglobin saturation or microvessel haematocrit. By process of elimination, the most likely explanation for the change in blood flow and oxygenation is a drug-induced change in blood viscosity. We subsequently showed that flunarizine reduces blood viscosity in vitro in conditions that simulate the tumour microenvironment (hypoxia, lactic acidosis) (Kavanagh et al., 1993) . In rat red blood cells, the optimal drug concentration to achieve this effect is 5-lOmgl-'. In contrast, 50mgl1' yields viscosities not unlike those from non-drug-containing control conditions. Parallel studies of cell density and morphology clearly demonstrate that this parabolic dose effect on viscosity is related to achieving an optimal red cell surface area-volume ratio that is most conducive to deformability. High doses lead to spherocytosis (swelling), which reduces deformability. The results of this current study are in agreement with our prior work with this drug in that the optimal dose range for modification of tumour blood flow was 1-5 mg kg-', while doses of 60 mg kg-' failed to exhibit any rheological change conducive to modification of tumour blood flow (Kavanagh et al., 1993) . This result is also consistent with prior work by Wood and Hirst (1989) , who demonstrated that optimal radiosensitisation of a murine tumour model was achieved at flunarizine doses of 4-5mgkg-' given i.p. Doses in the range of 50mgkg-' did not result in radiosensitisation.
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It has been reported previously that calcium channel blockers (verapamil and flunarizine) enhance melphalan retention and increase its activity in tumours (Robinson et al.. 1986 ). These prior results are somewhat difficult to compare with our study because the physiological data were less complete. Direct measurement of cardiovascular function is necessary for interpretation of results, particularly with calcium channel blockers that have more direct chronotropic and inotropic effects than flunarizine, such as verapamIil (Godfraind et al.. 1986) . In the prior studies, measurements of relative blood flow were made with rubidium-86 uptake. which measures fraction of cardiac output rather than tissue perfusion. Therefore, the effects of the calcium channel blockers on tissue blood flow caused by primary effects on cardiac function would not necessarily be determined. Calcium channel antagonists such as nimodipine and diltiazem have been reported to affect Na+. K+-ATPase activity (Godfraind et al.. 1986) . and 'Rb is a potassium analogue. Use of a potassium analogue to monitor changes in tissue blood flow. then, may produce artifactually influenced results in the presence of calcium channel blockers.
Calcium channel blockers and calmodulin inhibitors have been the subject of extensive investigation as chemosensitisers. particularly in regard to modification of drug resistance. The most active work has been related to modification of MDR. although some work has also been done in non-MDR tumours. We chose to study flunarizine in this context because it is both a calcium channel blocker and a calmodulin antagonist (Lugnier et al., 1984) . In addition. flunarizine has been reported to have some antiproliferative activity on its own, presumably via the calmodulinmodulated inhibition of DNA synthesis (Sezzi et al., 1984) . We chose flunarizine instead of other available calcium channel blockers for several reasons. First. other drugs that have been studied for this type of application, such as verapamil. do not have calmodulin-modulating activity in a dose range achievable in iOvo. Secondly. flunarizine, unlike similar drugs. could be administered over a wide dose range without appreciable effects on cardiovascular function (Godfraind et al., 1986) . Our physiological results verified the previous reports. There were no deaths from flunarizine from either dose. and no increase in frequency of deaths from melphalan or cyclophosphamide toxicity when flunarizine was added. Follow-up times post therapy were greater than 30 days in the TE-671 group, even at the highest melphalan dose administered (18 mg kg-'). which is 75% of the LD,O. Since no deaths were observed in this group. the dose-modifying factor for toxicity must be less than 1.0 0.75 or 1.33. In addition, plasma pharmacokinetics was not altered by the mild drop in blood pressure at the 60 mg kg-' dose of flunarizine. suggesting that renal function was unaltered.
In conclusion, the results of this study demonstrate that flunarizine, given at a high dose (60 mg kg-'). can create sensitisation to melphalan cytotoxicity with a dose-modifying factor ranging from 1.5 to 2.3. The enhancement of drug effect is not related to changes in tissue blood flow, but is significantly correlated with decreased drug egress from tumours. Parallel studies of cyclophosphamiide showed no enhancement of drug sensitivity. suggesting that the effects of flunarizine are operational on drug uptake or egress mechanisms that are specific for melphalan.
